- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.06. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to Shareholders | 862 | PR Newswire | ZURICH, June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 06.06. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 21.05. | NLS Pharmaceutics präsentiert Mazindol-Studie auf ASCP-Tagung | 2 | Investing.com Deutsch | ||
| NLS PHARMACEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.05. | NLS Pharmaceutics to present Mazindol study at ASCP Meeting | 2 | Investing.com | ||
| 16.05. | NLS Pharmaceutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 05.05. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.04. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.04. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.04. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models | 304 | PR Newswire | Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics
Favorable results support potential expansion into high-value... ► Artikel lesen | |
| 31.03. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.03. | NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement | 505 | ACCESS Newswire | The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd.(NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage... ► Artikel lesen | |
| 10.03. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.03. | NLS Pharmaceutics kündigt Fusion mit Kadimastem an | 2 | Investing.com Deutsch | ||
| 27.02. | NLS Pharmaceutics reports progress in narcolepsy treatment | 1 | Investing.com | ||
| 27.02. | NLS Pharmaceutics Ltd.: NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform | 325 | PR Newswire | ZÜRICH, Switzerland, Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon... ► Artikel lesen | |
| 25.02. | NLS Pharmaceutics Ltd.; Kadimastem Ltd.: Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment | 367 | PR Newswire | Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH and NESS ZIONA, Israel... ► Artikel lesen | |
| 25.02. | NLS Pharmaceutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,110 | +4,37 % | EQS-Adhoc: Evotec SE: Evotec passt Umsatzprognose an und bestätigt Gewinnprognose | EQS-Ad-hoc: Evotec SE / Schlagwort(e): Prognoseänderung
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
21.07.2025 / 11:25 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,255 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| IMMUNOVANT | 18,320 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| QIAGEN | 43,580 | +1,99 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 14,630 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| JANUX THERAPEUTICS | 25,970 | 0,00 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating | ||
| VERVE THERAPEUTICS | 11,130 | 0,00 % | Lilly completes tender offer for Verve Therapeutics shares | ||
| VIR BIOTECHNOLOGY | 5,760 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| SANA BIOTECHNOLOGY | 5,125 | 0,00 % | Citi Maintained a Buy Rating on Sana Biotechnology (SANA) | ||
| BEAM THERAPEUTICS | 20,960 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 27,545 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 14,950 | 0,00 % | EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics | CANBERA (dpa-AFX) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,310 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| UPSTREAM BIO | 13,350 | 0,00 % | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
| VALNEVA | 3,276 | -4,77 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen |
NLS PHARMACEUTICS LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,150 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NLS PHARMACEUTICS LTD finden Sie auf Wallstreet Online.